Conveying Information about Compounded Medicines: A Cross-sectional Pilot Study on Melatonin Liquid


  • Forrest Tang 3rd year BPharm(Hons) - University of Newcastle, NSW, Australia
  • Chelsea Bruderlin 3rd year BPharm(Hons) - University of Newcastle, NSW, Australia
  • Ashlee Lanfranchi 4th year BPharm(Hons) - University of Newcastle, NSW, Australia
  • Therése Kairuz Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, Australia


compounded medicines, melatonin, melatonin liquid, quality use of medicines, consumer medicines information


Background: Manufactured melatonin liquid is not available as a proprietary product in Australia, and when prescribed for children, is supplied as a compounded product. It may be challenging for a parent/carer to find reliable product information on compounded medicines, as there is no available standardised information or leaflet. 

Aim: The aim was to develop an information leaflet on extemporaneously prepared melatonin liquid for parents and carers, and to evaluate its readability and acceptability.

Method: A leaflet was designed following guidelines for written information.  For evaluation of the leaflet, a questionnaire was developed in consultation with a statistician and a pharmacy academic, and was piloted for face validity. The questionnaire elicited feedback about the leaflet design and content, and collected key participant demographics. The prototype leaflet and questionnaires were distributed to a convenience sample of five pharmacies in New South Wales.

Results: All participants (i.e. parents/carers) (n=16) felt that it was important to receive written information for melatonin liquid, and found the leaflet easy to understand. Most (94%; n=15) felt that they learnt something new after reading the leaflet, although three (19%; n=3) had unanswered questions, and nearly one-third (31%; n=5) felt somewhat concerned after reading the adverse reactions section of the leaflet.

Conclusion: The leaflet about compounded melatonin liquid was deemed acceptable by parents/carers.


Pharmaceutical Society of Australia. National Competency Standards Framework for Pharmacists [Internet]. 2016 [cited 2021 Jul 22]. Available from:

Therapeutic Goods Administration (TGA). Therapeutic Goods Administration (TGA) [Internet]. 2021 [cited 2021 Dec 26]. Available from:

Day R. Off-label prescribing. Aust Prescr [Internet]. 2013 [cited 2021 Dec 26];36:5-7. Available from: doi: 10.18773/austprescr.2013.075

Tasmanian Government. CCP Clinical Guideline 7: Off-Label Use of Medications. [PDF file from internet]. Hobart, Tasmania: Tasmanian Government; 2021 [cited 2021 Dec 26]. Available from:

Pharmacy Board of Australia. Guidelines on Compounding of Medicines. [PDF file from internet]. Melbourne, Victoria: Pharmacy Board of Australia; 2015 [cited 2021 Nov 22]. Available from:

Therapeutic Goods Administration. Consumer Medicines Information (CMI) – Therapeutic Goods Administration [Internet]. Canberra, Australia: Therapeutic Goods Administration; 2020 [cited 2021 Nov 22]. Available from:

Hamrosi KK, Raynor DK, Aslani P. Pharmacist, general practitioner and consumer use of written medicine information in Australia: Are they on the same page? Res Soc Adm Pharm [Internet]. 2014 [cited 2021 Dec 26];10(4):656-668. Available from: doi: 10.1016/j.sapharm.2013.10.002

The Sleep Health Foundation. Melatonin [Internet]. North Strathfield, New South Wales: The Sleep Health Foundation; 2021 Nov 18 [cited 2021 Dec 26]. Available from:

AMH Australian Medicines Handbook [Internet]. Adelaide, South Australia: AMH Australian Medicines Handbook; 2022. Melatonin: [modified 2021 Jan; cited 2022 Jan 12];[about 1 screen]. Available from:

Therapeutic Goods Administration. Australian Public Assessment Report for Melatonin [PDF file from internet]. Canberra, Australia: Therapeutic Goods Administration; 2009 [cited 2020 Mar 04]. Available from

Therapeutic Goods Administration. The Poisons Standard (The SUSMP) [Internet]. Canberra, Australia; 2021 [cited 2021 Jan 04]. Available from:

MIMS Online [Internet]. Sydney, New South Waled: MIMS Australia; 2021 [cited 2021 Nov 22]. Available from:

Australian Society of Compounding Pharmacists. Who we are [Internet]. Australian Society of Compounding Pharmacists. 2021 [cited 2021 Dec 26]. Available from:

Pharmaceutical Society of Australia. Australian Pharmaceutical Formulary and Handbook. 24 ed. Deakin West, Australian Capital Territory: Pharmaceutical Society of Australia; 2018.

eTG complete [Internet]. Melbourne, Victoria: Therapeutic Guidelines Ltd; 2020 Mar [cited 2021 Dec 26 06] Available from:

Doak C, Doak L, Root J. Teaching patients with low literacy skills [Internet]. 2nd ed. Philadelphia: J.B. Lippincott; 1996 [cited 2020 March 06]. Available from:

Dickinson R, Hamrosi K, Knapp P, et al. Suits you? Int J Pharm Prac [Internet]. 2012 [cited 2020 Mar 06];21(4):207-215. Available from: doi: 10.1111/j.2042-7174.2012.00252.x

Young A, Tordoff J, Moore S, Smith A. Patients’ views of general practitioners’ provision of medicine information leaflets. J Prim Health Care [Internet]. 2019 [cited 2020 Mar 06];11(4):359-366. Available from: doi:10.1071/HC19011

Tong V, Raynor DK, Blalock SJ, Aslani P. Exploring consumer opinions on the presentation of side-effects information in Australian Consumer Medicine Information leaflets. Health Expect [Internet]. 2016 [cited 2020 Mar 06];19(3):543-56. Available from: doi:10.1111/hex.12215

Bramble D, Feehan C. Psychiatrists’ Use of Melatonin with Children. Child Adolesc Ment Health [Internet]. 2005 [cited 2021 Dec 06];10(3):145-149. Available from: doi:10.1111/j.1475-3588.2005.00358.x

Kessels RP. Patients' memory for medical information. J R Soc Med [Internet]. 2003 [cited 2021 Dec 06];96(5):219-222. Available from: doi:10.1258/jrsm.96.5.21